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Abstract 
 
In various types of malignancies, conventional therapies such as surgery, radiation and chemotherapy 
are often ineffective. The identification of dependencies on signaling proteins and pathways specific to 
cancer cells, has resulted in the development of new therapies with enhanced selectivity and efficacy 
and reduced toxicity. We have recently shown that PRKD2 is a crucial regulator of tumor cell  
endothelial cell communication in gastrointestinal tumors and demonstrated the kinase to be a 
regulator of glioblastoma growth. Here we report that HSP90/CDC37 chaperone complex binds to and 
stabilizes PRKD2 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally 
divergent small molecules currently in clinical development, induced proteasome-mediated 
degradation of PRKD2 and was associated with augmented apoptosis in human cancer cells of 
various tissue origin. Ectopic expression of PRKD2 protected cancer cells from the apoptotic effects 
of HSP90 abrogation and restored blood vessel formation in two animal models. We further 
demonstrate that PRKD2 is essential for hypoxia-induced HIF-1 accumulation and NF-B activation 
in tumor cells. Moreover, overexpression of PRKD2 was able to partially restore HIF-1 protein levels 
and secreted VEGF-A in hypoxic cancer cells treated with HSP90 inhibitors. Taken together, our 
findings indicate that signals from hypoxia and HSP90 pathways are connected and further funneled 
by PRKD2 through the NF-B / VEGF-A axis to promote tumor growth and tumor angiogenesis. 
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Introduction 
Cancer development is a multistep process characterized by a multitude of genetic and epigenetic 
changes that induce resistance to pro-apoptotic stimuli, sustain angiogenesis and confer insensitivity 
to antigrowth signals and immune surveillance (1).  
Rapid tumor growth often results in hypoxia, which triggers the stabilization of the transcription factor 
hypoxia-inducible factor-1 (HIF-1), an oxygen sensor that controls the expression of multiple target 
genes implicated in angiogenesis, metabolism and cell survival (2, 3).  A prominent target of HIF-1 is 
the vascular endothelial growth factor A (VEGF-A) which induces tumor angiogenesis by stimulating 
proliferation, survival and migration of endothelial cells (4). HIF-1 has been reported to physically 
interact with heat shock protein 90 (HSP90) (5, 6) which can be targeted by small molecule inhibitors 
of chaperone, a growing class of clinically utilized anti-tumorigenic agents. HSP90 is a highly 
conserved and ubiquitously expressed molecular chaperone involved in the correct folding and final 
maturation of a plethora of proteins, so-called HSP90 clients, in an effort to maintain cellular 
homeostasis (7, 8). There are more than 200 HSP90 clients known including protein kinases, 
transcription factors and steroid hormone receptors (9 - 11). HSP90 is recruited to its kinase clients 
through interactions with kinase-specific co-chaperone CDC37 (12, 13), which stabilizes the 
HSP90/kinase (14). In tumor cells, HSP90 aids in folding dysregulated oncoproteins helping to sustain 
their aberrant activity. Amongst the most known client kinases of HSP90 are SRC (15), AKT (16), 
PDK-1 (17) and PKC (18). The latter was shown to directly activate protein kinase D (PRKD) family 
members via phosphorylation at two critical serine residues within the activation loop of the kinase 
catalytic domain (19). Recently, an affinity-based proteomic screen conducted to identify cancer-
specific networks coordinated by HSP90 revealed PRKD2 as a potential client for the chaperone in 
chronic myeloid leukemia (CML) cells (20). The serine-threonine kinase PRKD2 and its sister 
isoforms PRKD1 and PRKD3 belong to the calcium/calmodulin-dependent protein kinase superfamily 
(21) and are activated by various stimuli including phorbol esters, reactive oxygen species (ROS), 
receptor tyrosine kinases and hypoxia (22 - 24). PRKD2 expression and activity correlates positively 
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with the state of de-differentiation in lymphoma (25) and was demonstrated to be involved in myeloid 
leukemia by activating NF-B transcription factors (26). Furthermore, PRKD2 is involved in migration, 
invasion and growth of glioblastoma and pancreatic cancer cells (27 - 29). We have recently identified 
PRKD2 as a crucial mediator of hypoxia-induced VEGF-A expression and secretion in pancreatic 
cancer cells (24). 
The aim of this study was to interrogate the contribution of PRKD2 to HSP90-mediated tumor growth 
and tumor angiogenesis. In addition, the involvement of PRKD2 in the regulation of hypoxia-mediated 
HIF-1 stabilization, NF-B activation and VEGF-A production in the context of pharmacologic 
inhibition of HSP90 represented a major focus of our work. We identified PRKD2 as a novel client of 
HSP90 and revealed its requirement for tumor viability and tumor angiogenesis during abrogation of 
chaperone activity in vitro and in vivo. The fact that HSP90 regulates the stability of PRKD2, which 
acts as a two-pronged protein mediating tumor blood vessel formation via hypoxia-induced HIF-1 
stabilization, VEGF-A production and tumor vascularization on the one hand and cancer cell viability 
on the other, makes HSP90 inhibition a strategy to target two cancer characteristics with one drug. 
Our work shows that  	
	

  /convergence/nodal point  appears not only 
integrate but also to funnel/further transmit hypoxia and chaperone molecular signals to activate a 
crucial family of transcription factors, namely the NF-B and their target gene VEGF.  
In conclusion, our data indicate that HSP90 inhibitors (PU-H71 and STA-9090) currently undergoing 
clinical evaluation in patients might be used to target cancer growth and blood vessel formation 
particularly in hypoxic tumors with high expression of PRKD2. Given current efforts to develop PRKD2 
kinase inhibitors, we envision the combined use of HSP90 and PRKD2 kinase inhibitors to achieve 
synergistic effects. 
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Material and Methods 
 
For details, see Supplementary Data.  
 
Cell lines and inhibitors 
Cancer cell lines originating from ATCC were cultured in early passages in DMEM (Invitrogen, 
Germany) supplemented with 10% fetal calf serum (FCS: PAA, Germany), 1% penicillin/streptomycin 
and 5 μg/ml Plasmocin Prophylactic (InvivoGen). HCT-116 colon cancer cells were maintained in 
McCoy media supplemented with 10% FCS. MG-132 was obtained from Sigma-Aldrich, bortezomib 
was purchased from LC Laboratories. PU-H71 was synthesized as reported (30). STA-9090 was 
purchased from SelleckChem. 
 
Plasmids, transfection and lentiviral transduction 
The Block-IT Pol II miR RNAi sequences (#NM_016457.3-1295 and #NM_016457.3-1295-2019, 
Invitrogen) targeting human PRKD2 cloned into pLenti6.4CMV/R4R2/V5-DEST vector via Gateway 
technology (Invitrogen) used for lentiviral mediated knock-down were described previously (24). The 
pLenti6.2-V5-DEST-PRKD2 overexpression vector was generated using the pDONR-223-PRKD2 
entry clone from Addgene (#23490). High-titer virus-containing supernatants of 293FT after transient 
co-transfection of lentiviral vectors with pMD2 and psPAX2 viruses were used for lentiviral mediated 
transduction of cancer cells.  
 
CAM assay  
HCT-116 or MDA-MB231 cancer cells (1 x 106) were xenografted within 5 mm silicon rings on the 
surface of the chorionallantoic membrane (CAM) 8 days after fertilization. HSP90 inhibitor was 
delivered ectopically 24 and 48 hours after tumor xenograft at a concentration of 1 μM in serum-free 
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media. Four days after implantation, tumors were retrieved, fixed in formalin and further subjected to 
immunohistochemistry. 
 
Immunohistochemistry of CAM and mouse tumors 
Formalin-fixed tumors were embedded in paraffin using standard procedures. The 5 μm sections were 
processed and stained with antibodies directed against PRKD2 (1:250; Abcam #ab51250); pan-
cytokeratin (1:80; Dako, clone AE1/AE3); desmin (1:80; Dako, clone D33); von Willebrand Factor VIII 
(1:100; Biocare Medical, #CP039B); and Ki67 (1:100; Dako, clone MIB-1). Apoptotic cells were 
detected by TUNEL using the In Situ Cell Death Detection Kit, POD (Roche, # 11684817910) and 
quantified by counting >700 cells from at least four microscopic fields. 
 
Mouse xenotransplantation experiments 
All animal experiments were conducted according to German Animal Welfare and research protocols 
were approved by the Animal Care and Use Committee at the Regierungspräsidium Tübingen, 
Germany (TV-1153). MDA-MB231 breast cancer and HCT-116 colon cancer cells (5 x 106 each) were 
subcutaneously inoculated at the left and right dorsal sides of  6 week old female athymic mice 
(NMRI-(nu/nu), Janvier Labs, Le Genest-Saint-Isle, France. Each experimental group consisting of 9 
animals received either 75 mg per kg body weight PU-H71 i.p. three times/week or PBS as vehicle. 
Tumor size was monitored and measured for the next 3 weeks. After tumor retrieval, tumor volume 
was calculated according to the formula 0.5xLxWxT (L, length; W, width; T, thickness). Tumors were 
further processed for immunohistochemistry. 
 
Statistics 
Analyses were performed with GraphPad Prims 5.0. Statistical significance was assessed by an 
unpaired student t test. p<0.05 was considered significant. 
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Results 
 
Using an affinity-based proteomic assay followed by chemical precipitation and western blotting 
validation, Moulick and colleagues (20) identified PRKD2 as a putative HSP90 client in K562 CML 
cells. In order to assess whether HSP90 is able to bind to PRKD2 in solid tumors, 
coimmunoprecipitation experiments with pancreatic cancer cells (PaTu2) ectopically expressing GFP-
PRKD2 were conducted (Fig. 1A). PRKD2 interacted not only with HSP90 but also with the kinase-
specific co-chaperone CDC37 (Fig. 1A). To investigate whether the stability of PRKD2 requires 
HSP90, we performed knock-down experiments using short hairpin RNAs (shRNAs) targeting 
HSP90 (shHSP90) or HSP90 (shHSP90) respectively. shRNA-mediated abrogation of both 
HSP90 isoforms resulted in a decrease of PRKD2 protein levels in lung cancer A549 and breast 
cancer MDA-MB-231 cell lines (Fig. 1B and 1C) and this was associated with induction of apoptosis 
as revealed by enhanced PARP cleavage in western blot analysis (Fig. 1B and 1C). These data 
identify PRKD2 as a novel HSP90 client in epithelial tumor cells and suggest PRKD2 depletion via 
HSP90 inhibition as a potential strategy to target cancer cells.  
HSP90 is highly expressed in many tumors and allows the activation of tumor-specific signaling 
pathways and buffering stress conditions in the tumor microenvironment (31). Therefore, several 
ATP-competitive HSP90 inhibitors targeting a wide range of malignant tumors are currently under 
clinical investigation (1, 20, 32). To investigate whether PRKD2 stability is affected after 
pharmacologic HSP90 inhibition, eight human cancer cell lines representing six different tumor types 
(breast cancer, pancreatic cancer, lung cancer, colon cancer, acute myeloid leukemia (AML) and 
glioblastoma) were incubated for 24 hours with increasing concentrations of two different compounds: 
PU-H71, an optimized water soluble member of the purine class of HSP90 inhibitors (20) and STA-
9090, a resorcinol-containing triazole molecule with a novel chemical structure, both unrelated to the 
geldanamycin class of HSP90 inhibitors (1). Both inhibitors caused dose-dependent degradation of 
PRKD2 in all tumor cell lines (Fig. 1D and S.1). HSP90 inhibition-mediated PRKD2 degradation was 
associated with increased apoptosis as revealed by augmented PARP and caspase 9 cleavage in all 
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tumor cell lines (Fig. 1D and S.1). The enhanced cleaved caspase 9 indicates apoptosis induction via 
mitochondrial pathway. To prove that HSP90 inhibition-mediated depletion of PRKD2 contributes to 
the induction of cell death in tumor cells, we first sought to investigate whether down-regulation of 
PRKD2 preceded the induction of apoptosis. Pancreatic and breast cancer cell lines were incubated 
with either PU-H71 or STA-9090 for 4, 8, 12, 16, 20 and 24 hours and PRKD2 and cleaved PARP 
protein levels were assessed by western blotting (Fig. 1E). Degradation of PRKD2 commenced after 
4 hours  (PaTu2) or 8 hours (MDA-MB-231) and was followed by PARP cleavage at around 12 hours 
in both tumor cell lines, indicating causality between the reduction of PRKD2 protein levels and 
induction of apoptosis (Fig. 1E). To further substantiate that PRKD2 is crucial for killing cancer cells 
after HSP90 inhibition, we ectopically expressed a GFP-PRKD2 construct in three cancer cell lines 
(MDA-MB-231, A549 and PaTu2), treated them with PU-H71 and analyzed PRKD2 levels and PARP 
cleavage by western blotting. Both endogenous and overexpressed PRKD2 were subject of 
degradation; however the higher remaining PRKD2 protein levels partially rescued cell viability after 
HSP90 inhibition (Fig. 2A). We confirmed these results using a second approach and measured 
apoptosis by annexin V staining in MDA-MB-231 cancer cells after incubation with PU-H71 for 24 
hours. Enforced expression of PRKD2 resulted in near complete rescue of cell viability (Fig. 2B). 
Conversely, overexpression of a kinase-inactive mutant of PRKD2 (GFP-PRKD2-KD) did not prevent 
cell death triggered by pharmacologic abrogation of HSP90 activity in MDA-MB-231 and PaTu2 
cancer cells, suggesting the involvement of PRKD2 kinase activity in tumor cell viability (Fig. 2C).  
We next characterized the mechanism of PRKD2 degradation after treatment with PU-H71. To assess 
whether PRKD2 is degraded via the lysosomal pathway, we treated MDA-MB-231 breast cancer and 
A549 lung cancer cells with the lysosome inhibitor NH4Cl before PU-H71 incubation. Western blot 
analysis testing the abundance of PRKD2 protein in the detergent-soluble and detergent-insoluble 
fractions showed that preincubation with NH4Cl did not result in an increase of PRKD2 levels 
compared with the HSP90 inhibitor treatment alone, indicating that PRKD2 is not degraded via the 
lysosomal pathway (S.2A). In contrast, pretreatment of A549 and MDA-MB-231 cell lines with two 
different proteasome inhibitors, bortezomib or MG-132, followed by incubation with PU-H71 rescued 
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PRKD2 levels and resulted in redistribution of PRKD2 to the detergentinsoluble fraction (Fig. 2D and 
S.2B). Consistent with its degradation via the proteasomal pathway, PRKD2 was extensively 
ubiquitinated in 293T cells transiently overexpressing PRKD2 after treatment with PU-H71 in 
combination with bortezomib (Fig. 2E). Together, these findings indicated that degradation of PRKD2 
upon HSP90 inhibition occurs via the proteasomal pathway.  
We previously reported a crucial role for PRKD2 in tumor angiogenesis and cancer cell proliferation 
(24, 27). We therefore sought to investigate whether PRKD2 depletion via HSP90 inhibition might 
impair tumor growth and blood vessel formation using a CAM xenotransplantation assay. MDA-MB-
231 breast cancer and HCT-116 colon cancer cells stably expressing PRKD2 or empty vector were 
xenografted on the surface of chicken CAM eight days after egg fertilization. The in vivo efficacy of 
PU-H71 has been previously tested (33). PU-H71 was ectopically applied 24 hours and 48 hours after 
implantation and tumor growth was monitored. 72 hours after implantation tumors were excised, 
photographed and analyzed by immunohistochemistry (IHC). Treatment with PU-H71 of cancer cell 
lines expressing empty vector resulted in a significant decrease in tumor size (Fig. 3A and 3B). IHC 
analysis showed pronounced PRKD2 degradation upon HSP90 inhibition, which was associated with 
a significantly reduced proliferation rate as measured by Ki67 staining, and increased apoptosis as 
determined by TUNEL analysis (Fig. 3C, 3D, 3E and S.3A and S.3B). Examination of tumor-driven 
vascularization in xenografts revealed a marked reduction of blood vessel density, as determined by 
desmin and von Willebrand Factor (vWF) staining upon PU-H71 treatment compared to tumors 
treated with vehicle (Fig. 3C and 3F). Overexpression of PRKD2 was able to revert all PU-H71-
induced effects as demonstrated by restored tumor formation (Fig. 3A and 3B), enhanced tumor 
proliferation (Fig. 3C, 3D and S.3A), impaired apoptosis (Fig. 3C, 3E and S.3B) and restored blood 
vessel formation (Fig. 3C and 3F).  
To further substantiate the data obtained in the CAM model, we examined the effects of HSP90 
inhibition-mediated PRKD2 degradation in an additional in vivo model. HCT-116 colon carcinoma and 
MDA-MB-231 breast cancer cells stably overexpressing PRKD2 or empty vector were injected 
subcutaneously into both flanks of nude mice. One week later when tumors were palpable, mice 
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received either 75 mg PU-H71 per kg body weight or vehicle (PBS) i.p. three times per week. After 
three weeks, mice were sacrificed and tumors were analyzed. In line with the CAM experiments, 
pharmacologic inhibition of HSP90 resulted in substantially decreased tumor growth, increased 
apoptosis and impaired angiogenesis in tumors expressing control vector (Fig. 4A-F, S.4A, S.4B, 
S.5A and S.5B). Conversely, administration of PU-H71 to mice that received cancer cells 
overexpressing PRKD2 showed little effect. Tumors from PBS treated mice and tumors 
overexpressing PRKD2 from PU-H71 treated mice were associated with less TUNEL-positive cells 
(Fig. 4D, 4F, S.4A and S.4B), increased vWF expression (Fig. 4D and 4E) and higher number of 
Ki67-positive tumor cells as compared to tumors transduced with empty vector and treated with PU-
H71 (S.5A and S.5B). These data are in line with our previous finding that PRKD2 plays a major role 
in tumor growth and tumor angiogenesis and suggest that these properties can be counteracted by 
HSP90 inhibition-mediated PRKD2 depletion. 
VEGF-A is one of the most potent mediators of the formation of blood vessels both under 
physiological and pathological conditions. We have previously reported that PRKD2 ablation impairs 
hypoxia-induced VEGF-A expression and secretion in pancreatic cancer cells (24).  Since hypoxic 
upregulation of VEGF-A occurs mainly via the stabilization of HIF-1 we sought to investigate 
whether PRKD2 might regulate VEGF-A via this sensor protein. shRNA-mediated depletion of PRKD2 
in pancreatic (PaTu2) and lung (A549) cancer cells abrogated hypoxia-induced accumulation of HIF-
1 protein (Fig. 5A). In addition, depletion of PRKD2 in tumor cells almost completely prevented the 
transcriptional activation of the HIF-response element (HRE), a HIF-1 docking site present in 
promoters that contain the NCGTG sequence (Fig. 5B). HIF-1 has been reported to be an HSP90 
client (6, 33). In line with this, shRNA-mediated depletion of HSP90 and pharmacologic HSP90 
inhibition in breast cancer cells resulted in impaired hypoxia-induced HIF-1 accumulation (Fig. 5C 
and 5D). In both cases, abrogation of HIF-1 protein stability was associated with decreased hypoxia-
induced intracellular VEGF-A levels (Fig. 5C and 5D).  
We next considered whether PRKD2 is involved in hypoxia-induced stabilization of HIF-1 during 
HSP90 inhibition. Therefore, cancer cell lines stably transduced with PRKD2 or empty vector were 
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incubated in low-oxygen atmosphere in the presence or absence of HSP90 inhibitor. As expected, 
treatment of tumor cells containing empty vector with PU-H71 impaired hypoxia-stabilized HIF-1 
levels (Fig. 6A and 6B). Overexpression of PRKD2 was able to partially rescue the hypoxia-induced 
accumulation of HIF-1 protein (Fig. 6A and 6B) and HRE promoter activity (Fig. 6C), resulting in 
restored VEGF-A levels secreted by MDA-MB-231 and HCT-116 cells (Fig. 6D). Together, these data 
suggest that hypoxia-induced stabilization of HIF-1 protein is mediated by HSP90 directly and 
through PRKD2, supporting a concept where PRKD2 links chaperone and hypoxia signaling 
pathways. VEGF-A can be secreted by tumor cells upon activation of HIF-1 and NF-B transcription 
factors (35). Furthermore, low oxygen environment was reported to promote not only the 
accumulation of HIF-1 but also to activate NF-B transcription factors via TAK1/IKK signaling (36). 
HSP90/CDC37 was shown to interact with the kinase domain of IKK/IKK and inhibition of HSP90 
by geldanamycin prevented TNF-induced activation of IKK and NF-B (37). We therefore wanted to 
know whether NF-B signaling might be connected to the hypoxic response regulated by PRKD2 and 
HSP90. Our experiments show that NF-B promoter activity is increased upon incubation of MDA-
MB-231 cells in low oxygen atmosphere (Fig. 6E and 6F). HSP90 inhibition resulted in impaired 
hypoxia-induced NF-B promoter and reduced binding activity (Fig. 6E and data not shown). 
Similarly, shRNA-mediated suppression of PRKD2 resulted in decreased luciferase production of the 
NF-B reporter (Fig. 6F).  We previously demonstrated that hypoxia-induced VEGF-A promoter 
activity, and intracellular and secreted VEGF-A levels are also impaired upon PRKD2 knock-down in 
cancer cells (24). Since hypoxia and HSP90 mediate their signals through the IKK complex towards 
NF-B which is also activated by PRKD2 (26, 48), we asked whether PRKD2 plays any role in this 
scenario. A triple active mutant of PRKD2 (PRKD2-S244/706/710E, PRKD2-3SE) was sufficient to 
enhance the NF-B promoter activity. Conversely, NF-B transcriptional activity was impaired upon 
co-expression of this construct with a non-degradable IB mutant (TD-IB) (Fig. 6G), suggesting 
that activation of NF-B by PRKD2 involves the phosphorylation and proteasomal degradation of 
IB. Enforced expression of PRKD2 was able to marginally restore the hypoxia-induced NF-B 
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promoter activity affected by the inhibition of HSP90 (S.6).   Taken together, these results favor 
PRKD2 as a kinase acting in both NF-B and HIF-1 pathways thereby integrating hypoxic signals 
and HSP90 chaperone function to promote tumor growth and tumor angiogenesis. 
 
 
Discussion 
 
HSP90 serves as an ATP-dependent stabilizer of diverse signaling proteins, including many kinases 
that are involved in cell proliferation and survival. Chaperone inhibitors were recently shown to 
effectively inhibit tumor cell growth and angiogenesis in hematologic and solid-organ malignancies. 
However, it remains elusive whether cancer cell killing or disruption of vasculature network supplying 
tumor cells is mediated by depletion of a single molecule or simultaneous degradation of multiple 
client proteins that are overexpressed and/or mutated in cancer (38).  
In this study, we have identified PRKD2 as a novel client of the HSP90 chaperone. Besides the 
interaction with HSP90, we could demonstrate that PRKD2 also interacts with CDC37, a co-
chaperone previously reported to recruit protein kinases to the HSP90 chaperone complex (39, 40). 
Notably, depletion of PRKD2 protein following pharmacologic inhibition of HSP90 dramatically 
enhanced tumor cell death in vitro in various human cancer cell lines, as well as in two in vivo 
xenograft models. These data not only confirm the role of PRKD2 as an anti-apoptotic signaling 
molecule (41, 42), but also implicate PRKD2 in the cell death evoked by HSP90 inhibition. Our earlier 
findings demonstrated that PRKD2 is a crucial mediator of tumor angiogenesis involving upregulation 
and secretion of VEGF-A (24).  This prompted us to investigate whether HSP90 might contribute to 
tumor angiogenesis through PRKD2 protein stabilization. We demonstrated that pharmacologic 
inhibition of HSP90 impaired blood vessel formation in vivo. The fact that PRKD2 overexpression 
restored vascularization and cell viability after HSP90 inhibition points to the involvement of PRKD2 in 
these HSP90 inhibitor-induced effects. Our data support PRKD2 degradation through HSP90 
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inhibition as a putative strategy to hit two important cancer characteristics - angiogenesis and cell 
viability - with one drug.  
HSP90 inhibitors have been reported to indirectly regulate HIF-1 (43 - 46). Furthermore, the HSP90 
inhibitor geldanamycin reduced hypoxia-mediated HIF-1 activation, indicating that chaperone activity 
is needed for this activation (6). The fact that HSP90 interacts both with HIF-1 (6) and PRKD2 (this 
study) prompted us to evaluate the contribution of PRKD2 with respect to HIF-1 stabilization in 
hypoxic tumors. We found that abrogation of PRKD2 in cancer cells prevented hypoxia-mediated HIF-
1 accumulation and HIF-1 promoter activity. In line with several reports, reduced HSP90 
expression and/or activity resulted in impaired hypoxia-triggered HIF-1 accumulation and decreased 
VEGF-A expression. Notably, ectopically expressed PRKD2 was able to partially restore HIF-1 
protein levels, HIF-1 transcriptional activity and secreted VEGF-A levels after pharmacologic HSP90 
inhibition. Together, these findings suggest that PRKD2 is required for hypoxia-induced HIF-1 
stabilization and that HSP90-supported angiogenesis is modulated by PRKD2 in hypoxic tumors by 
regulating the accumulation of HIF-1 protein and subsequent VEGF-A secretion. 
VEGF-A can be produced by tumor cells upon activation of HIF-1 and NF-B (35). Hypoxia drives 
the accumulation of HIF-1 but also activates NF-B transcription factors (36). Furthermore, inhibition 
of HSP90 was shown to promote apoptosis through suppression of AKT/NF-B signaling (47). Thus, 
NF-B represents a downstream effector of two major signaling routes:  the hypoxia-induced HIF-1 
and HSP90 pathways. Since PRKD2 was reported to mediate stress-induced NF-B activation and 
cell survival (48), we reasoned that PRKD2 acts upstream of NF-B and might be a crucial molecule 
to funnel hypoxia/HIF-1 and HSP90 signals down to NF-B and subsequently to VEGF-A 
expression/secretion. We found that hypoxia-induced NF-B activation was blocked by HSP90 
inhibition and shRNA-mediated suppression of PRKD2. The finding that PRKD2 was able to just 
marginally restore hypoxia-induced NF-B promoter activity affected by the inhibition of HSP90 
suggests that other factors might be required as well to funnel HSP90 angiogenic signals through NF-
B pathway. 
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In conclusion, our data suggest a central role for PRKD2 to enhance HIF-1 accumulation in low-
oxygen environment. Stabilization of PRKD2 by HSP90 also results in the activation of NF-B and its 
target VEGF-A, which promotes cancer cell growth and increases blood vessel formation in hypoxic 
tumors (Fig. 7). Whether PRKD2 activates NF-B / VEGF-A via upregulation of HIF-1 in hypoxic 
tumors or whether it contributes to the parallel activation of distinct HIF-1 / VEGF-A or NF-B / 
VEGF-A pathways remains to be elucidated. This study may also have clinical implications since 
several HSP90 and PRKD2 inhibitors are currently in clinical trials or under development. The 
combination of HSP90 and PRKD2 inhibitors might have synergistic effects in patients with hypoxic 
tumors expressing high levels of PRKD2. 
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Figure legends 
 
Figure 1. Pharmacologic inhibition of HSP90 results in PRKD2 degradation and induces 
apoptosis. A, immunoprecipitation with anti-GFP antibody was performed with lysates of PaTu2 cells 
transiently transfected with either GFP-empty vector (e.v.) or a GFP-PRKD2 construct. Membranes 
were incubated with HSP90and Cdc37 antibodies. B, C, protein expression of HSP90, HSP90, 
PRKD2 and cleaved PARP was determined in cancer cell lines transduced with a non-targeting 
control shRNA (Scr) or a shRNA-targeting HSP90or HSP90. D, breast cancer (MDA-MB-231), 
pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116 and acute myeloid leukemia 
(AML) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. 
Western blot analysis with PRKD2, cleaved PARP and anti-cleaved caspase 9 are depicted. E, 
lysates of cancer lines incubated with 1μM PU-H71 for the indicated time points were subjected to 
western blot analysis with PRKD2 and cleaved PARP antibodies. 
 



Figure 2. Destabilization of PRKD2 is essential for HSP90 inhibition-triggered apoptosis in 
tumor cells. A, lysates of cancer cell lines transiently transfected with empty vector (e.v.) or GFP-
PRKD2-widtype (PRKD2-wt) and incubated with PU-H71 for 24 hours were subjected to western blot 
analysis with PRKD2 and cleaved PARP antibodies. Cleaved PARP bands were quantified by 
densitometric analysis using ImageJ program (right-hand panels). B, cancer cells transiently 
transfected with empty vector (e.v.) or PRKD2-wildtype (PRKD2-wt) and incubated with PU-H71 for 
24 hours were subjected to Annexin V / Propidium iodide staining. The bar graphs represent the 
means of Annexin V+/PI- cells. C, cancer cell lines transfected with a GFP-tagged kinase dead 
PRKD2 (PRKD2-KD) mutant and incubated with PU-H71 for 24 hours were subjected to western 
blotting. Membranes were incubated with PRKD2 and cleaved PARP antibodies. Cleaved PARP 
bands were quantified by densitometric analysis using ImageJ program (right-hand panels). D, 
Soluble and insoluble protein fractions of breast and lung cancer cell lines pre-treated with 
Bortezomib for 2 h before incubation with PU-H71 were subjected to western blotting. Membranes 
were incubated with PRKD2 antibody. E, 293T cells transfected with GFP-PRKD2 were treated as 
described in (B) and immunoprecipitation analysis was performed with anti-GFP antibody. 
Membranes were incubated with anti-Ubiquitin antibody.  
 
Figure 3. HSP90 inhibition impairs tumor growth and tumor blood vessel formation on CAM in 
a PRKD2-dependent manner A, MDA-MB-231 or HCT-116 stably expressing PRKD2 (PRKD2-wt) or 
empty vector (e.v.) were delivered to CAM. 24 hours old tumors were treated with 1μM PU-H71 for 
the next 48 hours. Bar, 1.5 mm. B, quantification of tumor area is presented. Error bars represent 
mean +/- SEM of four to seven tumors. C, IHC of HCT-116 cells growing on CAM using specific 
antibodies directed against PRKD2, Ki67, desmin and von Willebrand factor (vWF) is presented. 
Parallel samples were subjected to TUNEL labeling.  D, quantification of Ki67 positive HCT-116 cells 
is shown. E, quantification of TUNEL-positive cells for colon cancer cell xenografted on chicken CAM 
is displayed. Error bars represent mean +/- SEM of at least four microscopic fields with 700 cells.  F, 


desmin immunoreactivity was quantified by subtracting background staining from specific desmin 
using Optima software. Scale bar indicates 125 μm.  
 
Figure 4. HSP90 inhibition decreases tumor growth and tumor blood vessel formation in nude 
mice in a PRKD2-dependent manner. A, PRKD2 expression in colon and breast cancer cell lines 
stably transduced with PRKD2 is presented. B, one week following subcutaneous tumor 
transplantation mice were injected with PU-H71. Three weeks later animals were sacrificed and 
tumors were analyzed. Photographs of five representative tumors per experimental group and cell line 
are depicted. C, the volume of explanted tumors was calculated. Graphs represent means +/- SEM of 
at least 14 tumors per experimental group and cell line as indicated in 4B. D, IHC analysis of 
xenografted HCT-116 tumors with antibodies against von vWF and TUNEL are displayed.  E, vWF 
labeling was quantified by subtracting the background staining using Optima software. F, 
quantification of HCT-116 TUNEL-positive tumor cells is presented. Error bars represent mean +/- 
SEM of at least four microscopic fields with 600 cells.  Scale bar indicates 125 μm. 
 
Figure 5. PRKD2 mediates hypoxia-induced accumulation and promoter activity of HIF-1 A, 
Pancreatic and lung cancer cell lines stably transduced with PRKD2-specific microRNA (miR-PRKD2) 
or a non-coding microRNA (miR-Scr) were incubated for 24 hours under low oxygen atmosphere. Cell 
extracts were subjected to western blot analysis with PRKD2 and HIF-1 antibodies. B, breast and 
lung cancer cell lines transduced with a PRKD2-specific miR were transiently transfected with 3xHRE-
luc and pTK-Renilla. Four hours after transfection cells were incubated under normoxic or hypoxic 
conditions and then cell lysates were subjected to luciferase assay. Bars are the means +/- SEM of at 
least three independent experiments. C, breast cancer cells transduced with a non-targeting control 
shRNA or HSP90 and HSP90-specific shRNAs were incubated under hypoxia or normoxia for 24 
hours and HIF-1 and VEGF-A levels were determined using western blot analysis. D, lysates of 
breast cancer cells incubated under low oxygen conditions or normoxia in the presence or absence of 


PU-H71 inhibitor were subjected to western blot analysis with HIF-1 and VEGF-A antibodies. No = 
normoxia; Hy = hypoxia.  
 
Figure 6. Ectopic PRKD2 restores hypoxia-induced stabilization of HIF-1after HSP90 
inhibition. A, B, lung and breast cancer cells transduced with control vector (e.v.) or PRKD2 
(PRKD2-wt) were incubated under hypoxic conditions or normoxia for 24 hours in the presence or 
absence of HSP90 inhibitor. Western blot analysis with HIF-1 and PRKD2 specific antibodies is 
presented. C, breast cancer cells overexpressing PRKD2 were transfected with 3xHRE-luc reporter 
and then incubated in hypoxic or normoxic environment in the presence or absence of HSP90 
inhibitor. Luciferase production was assayed. Bars are the means +/- SEM of three independent 
experiments. D, supernatants of breast and colon cancer cells stably overexpressing PRKD2 or 
empty vector and incubated in low oxygen in the presence or absence of PU-H71 were subjected to 
VEGF-A-specific ELISA. E, breast cancer cells transfected with 3x B-luc reporter were incubated in 
hypoxic or normoxic environment in the presence or absence of HSP90 inhibitor and cell lysates were 
subjected to luciferase assays. F, MDA-MB-231 cancer cells transduced with PRKD2-specific miR 
transfected with 3x-B-luc and pTK-Renilla were incubated under normoxic or hypoxic conditions. Cell 
lysates were subjected to luciferase assay. G, Lysates of MDA-MB-231 cells transfected with PRKD2-
wt, constitutive active PRKD2 (PRKD2-3SE) and trans-dominant IB mutant (TD-IB) were 
subjected to luciferase assay. For all experiments bars represent the means +/- SEM of at least three 
independent experiments. 
 
Figure 7. PRKD2 modulates HSP90-driven tumor growth and tumor angiogenic by regulating 
hypoxia-mediated HIF-1 stability and inducing VEGF-A secretion via activation of NF-B.  A, 
stabilization of PRKD2 by HSP90/Cdc37 chaperone/co-chaperone complex contributes to enhanced 
HIF-1 accumulation in low oxygen environment.  In this scenario, activation of NF-B and its target 
VEGF-A is associated with augmented tumor growth and increased blood vessel formation. B, 


degradation of PRKD2 following HSP90 inhibition affects HIF-1/VEGF-A and/or HIF-1/NF-
B/VEGF-A signaling pathways and triggers enhanced cancer cell apoptosis and impaired tumor 
vascularization. Dotted bold lines represent basal signaling in hypoxic tumors; dotted thin lines 
represent impaired signaling. 
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